Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016)

Summary

Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016) is a study catalogued by cBioPortal DataHub under the cancer-type code prad. EvidenceHelix groups it with prostate studies.

Study description

Whole exome sequencing of 114 metastatic tumor/normal pairs to understand genomic overlap between castration resistant adenocarcinoma (CRPC-Adeno) and neuroendocrine histologies (CRPC-NE).

Text as published in the source's study metadata.

Citation & PubMed

Beltran et al. Nat Med 2016

Linked PubMed records: PMID 26855148

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

nepc_wcm_2016

Short name

NEPC (Multi-Institute 2016)

Source cancer-type code

prad

Reference genome

not given

Source access groups

PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Beltran et al. Nat Med 2016

• PubMed record 26855148 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)

  Exome sequencing of 61 prostate cancer tumor/normal pairs (50 metastatic CRPCs and 11 high-grade localized prostate cancers). Generated by Arul Chinnaiyan's and Scott Tomlins' labs at the University of Michigan.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)

  Whole exome sequencing of 444 castrate resistant prostate cancer tumor/normal pairs. SU2C-PCF Dream Team: Precision Therapy for Advanced Prostate Cancer.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015)

  Whole-exome sequencing of 150 metastatic prostate cancer tumor/normal pairs by the SU2C/PCF Dream Team.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (Broad/Cornell, Cell 2013)

  Whole genome sequencing of 57 prostate tumor and matches normal tissues.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012)

  Whole-exome sequencing of 112 prostate adenocarcinomas and matched normal samples. Generated by Levi Garraway's lab at the Broad Institute and Mark Rubin's lab at Cornell.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (CPC-GENE, Nature 2017)

  Whole-genome/exome sequencing of 477 prostate samples from CPC-GENE and public data sets, including TCGA-PRAD.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (Fred Hutchinson CRC, Nat Med 2016)

  Whole-exome sequencing, array comparative genomic hybridization (CGH) and RNA transcript profiling of 176 tumors from 63 patients with disseminated prostate cancer with matched normals.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (SMMU, Eur Urol 2017)

  Whole-genome and transcriptome sequencing of 65 Prostate Adenocarcinoma tumor/normal pairs.

  ProstateOther published and consortium studiesSource code pradPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.